Interview with Hyun Ho Jung, CEO, Medy-Tox
What drove you to make the move from the academia to the business sector when you decided to establish Medy-Tox in 2000? I founded Medy-tox in the year 2000, in…
Address: Ochang Science Industry Complex 641-4 Gak-ri, Ochang-eup, Chungbuk 363-883, Republic of Korea
Tel: +82-43-217-1555
Web: http://www.medy-tox.co.kr/
Medy-Tox is a biotech venture company established in 2000 with a goal of developing botulinum toxin-based injections. Through the hard work and dedication of our employees, MEDITOXIN (‘NEURONOX, in the overseas market) was developed in 2006. MEdy -Tox’s products are very popular with not only domestic customers but also overseas customers and the demand for them is rapidly increasing annually. Medy Tox aims to become the best bio pharmaceutical manufacturer in Republic of Korea and to compete with the world’s biotech venture company. Medy Tox’s genuine efforts on next-generation botulinum products have been paying off one by one. Meditox will be able to provide our customers with a different product every year.
What drove you to make the move from the academia to the business sector when you decided to establish Medy-Tox in 2000? I founded Medy-tox in the year 2000, in…
Olive Healthcare is a startup developing wellness and medical devices services for the quantitative measurement of body composition, an integral part of the new healthcare paradigm based on prevention. Here,…
A Korean research team at Ulsan National Institute of Science and Technology (UNIST) have developed a cunning technology for treatments that attack cancer cells. Treatments that travel through the…
From Wednesday 31st October to Friday 2nd November, Seoul hosted the KoNECT-MFDS International conference, promoting South Korea’s clinical research capabilities on a global platform. The fourth of its kind, the…
Celltrion Healthcare, the marketing arm of the biopharmaceutical company Celltrion won a huge deal in France last Friday (2nd November 2018) with big tenders for Herzuma, a biosimilar of Roche’s…
Korea is fast becoming a big player in the pharmaceutical industry, especially within the biotech arena. With 4% of the total pipelines in the world, the country is showing strong…
Korean Pharma company, Hanmi has won orphan drug status this week from the US Food and Drug Administration (FDA) for HM43239, a drug for the treatment of acute myeloid leukaemia…
Local flagship company Boryung has found success with its newly developed angiotension receptor blocker (ARB) Kanarb. Nine molecules currently exist worldwide in this category of antihypertensives, and Kanarb is currently…
The growth of clinical trials in Korea has been remarkable in recent years. The number of clinical trials performed by multinationals has shot up from five in 2000 to 303…
Korea’s economy has been dominated for decades by chaebols, large family-owned business conglomerates like Samsung, Hyundai, and LG, known for their hierarchical structures and success in Korea’s traditional sectors. However,…
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their…
“When I left Janssen, I never imagined joining a Korean company,” recalls Choi Tae-Hung, sipping a freshly brewed yujacha tea in his office on a crisp autumn morning as he…
Minister Moon discusses the results of his recent state visit to the Middle East with Korea’s President, and Korea’s assets and potential as a global healthcare partner in developing and…
See our Cookie Privacy Policy Here
